These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Screening for colorectal cancer: the cost to find an advanced adenoma. McGrath JS, Ponich TP, Gregor JC. Am J Gastroenterol; 2002 Nov; 97(11):2902-7. PubMed ID: 12425566 [Abstract] [Full Text] [Related]
23. Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing. Wong CK, Lam CL, Wan YF, Fong DY. BMC Cancer; 2015 Oct 15; 15():705. PubMed ID: 26471036 [Abstract] [Full Text] [Related]
24. Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer. Limat S, Bracco-Nolin CH, Legat-Fagnoni C, Chaigneau L, Stein U, Huchet B, Pivot X, Woronoff-Lemsi MC. Eur J Health Econ; 2006 Jun 15; 7(2):107-13. PubMed ID: 16474968 [Abstract] [Full Text] [Related]
26. Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan. Miyazaki Y, Harada T, Akase T, Arakawa I, Inoue T. Clin Ther; 2009 Jun 15; 31 Pt 2():2433-41. PubMed ID: 20110051 [Abstract] [Full Text] [Related]
27. Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial. Lacas B, Bouché O, Etienne PL, Gasmi M, Texereau P, Gargot D, Lombard-Bohas C, Azzedine A, Denis B, Geoffroy P, Auby D, Michel P, Pignon JP, Lepage C, Ducreux M, Borget I. Expert Rev Pharmacoecon Outcomes Res; 2019 Oct 15; 19(5):601-608. PubMed ID: 30739558 [Abstract] [Full Text] [Related]
28. Cost-effectiveness modeling of colorectal cancer: computed tomography colonography vs colonoscopy or fecal occult blood tests. Lucidarme O, Cadi M, Berger G, Taieb J, Poynard T, Grenier P, Beresniak A. Eur J Radiol; 2012 Jul 15; 81(7):1413-9. PubMed ID: 21444171 [Abstract] [Full Text] [Related]
33. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany. Vijayaraghavan A, Efrusy MB, Göke B, Kirchner T, Santas CC, Goldberg RM. Int J Cancer; 2012 Jul 15; 131(2):438-45. PubMed ID: 21898389 [Abstract] [Full Text] [Related]
34. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ladabaum U, Chopra CL, Huang G, Scheiman JM, Chernew ME, Fendrick AM. Ann Intern Med; 2001 Nov 06; 135(9):769-81. PubMed ID: 11694102 [Abstract] [Full Text] [Related]
36. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. Buskermolen M, Cenin DR, Helsingen LM, Guyatt G, Vandvik PO, Haug U, Bretthauer M, Lansdorp-Vogelaar I. BMJ; 2019 Oct 02; 367():l5383. PubMed ID: 31578177 [Abstract] [Full Text] [Related]